Polymedix 8-K PolyMedix Announces Positive Results from Phase 2 Clinical Trial

Exhibit 99.2

OTCBB: PYMX

www.polymedix.com

Revolutionizing the Treatment of Infectious
Diseases with Defensin-Mimetics

PMX-30063 Phase 2 ABSSSI Clinical Trial
Results

April 23, 2012

Disclaimer and Safe Harbor

Forward-looking statements

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that
could cause PolyMedix’s actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has in some cases identified
forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,”
“expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other
factors that could cause actual results to differ materially from those expressed in forward-looking
statements are PolyMedix’s need for, and the availability of, substantial capital in the future to fund its
operations and research and development, and the fact that PolyMedix’s compounds may not successfully
complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the
United States or elsewhere. A more complete description of these risk factors is included in PolyMedix’s
filings with the Securities and Exchange Commission. You should not place undue reliance on any forward
-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to
any such forward-looking statements that may be made to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events, except as required by applicable
law or regulation.

1

PMX-30063 Defensin-Mimetic --- New Class of Antibiotic

Positive Phase 2 study results

•Showed consistently high clinical response rates with PMX-30063

•Safe and generally well-tolerated

•First efficacy study in patients with this new class of antibiotic

PMX-30063 is unique ---- our goal is to dominate the multi-
billion $ hospital antibiotic market

•Novel mechanism of action and reduced susceptibility to resistance
is key differentiator

2

The Urgent Need for New Antibiotics

“The world is on the brink of losing
these miracle cures.”

Dr. Margarete Chang, Director-General World Health Organization

   Many infections caused by highly resistant bacteria such as MRSA - 100’s of kinds

70% of infections resistant4

      Demand exists for truly novel antibiotics with differentiated properties

In US antibiotic-resistance causes:

$20 billion in excess healthcare costs1

$35 billion in societal costs1

8 million additional hospital days1

7 million MRSA infections/year U.S. 2

Up to 300,000 deaths3

1 http://www.cdc.gov/media/releases/2011/p0407_antimicrobialresistance.html

2 Archives of Internal Medicine, 2008, A.L. Hersh et.al.

3 B. Spellberg, Rising Plague, 2009

4 Association for Professionals in Infection Control & Epidemiology; Feb 2008

3

Learning from evolution to solve the problem:Killing bacteria the same way as the Host Defense Proteins

Target and directly disrupt

microbial membranes

Biophysical Approach

Host defense proteins

+ PMX-30063

Imitates natural immune
defense system

Rapidly bactericidal

Specific for bacteria

Evolutionarily conserved

+ Immunomodulatory activities

DNA

Ribosomes

Cell wall synthesis

Beta-lactams

Glycopeptides

Aminoglycosides

Macrolides

Tetracyclines

Fluoroquinolones

Sulfonamides

Biochemical Approach

Cell membrane depolarization

Lipopeptides

4

Potential Competitive Positioning:
PMX-30063 vs. Other Staph Antibiotics

	Macrolide class	Vancomycin (glycopeptides)	Linezolid (oxazolidinones)	Daptomycin (lipopeptides)	PMX-30063 (Defensin- mimetic class)
Short Dosing Schedule	ü			ü	ü
Bactericidal Activity				ü	ü
Gram+ and Gram- Activity					ü
Long post- antibiotic effect			ü	ü	üü
Anti-inflammatory activity	ü				ü
Anti-biofilm activity				ü	ü
Resistance unlikely					ü

5

PMX-30063 Phase 2 ABSSSI Clinical Trial

First efficacy study in patients with this new class of antibiotic -
defensin-mimetic, PMX-30063

Efficacy

•High clinical success rates

•At early time points and sustained over time

•PMX-30063 similar to active control

Safety

•In this study PMX-30063 was safe and generally well-tolerated

Successfully achieved study objectives

6

Phase 2 Clinical Trial -- Overview

Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
caused by Staph aureus:

•One of the most common infections in U.S.; >14 million/year1

Rigorous study entry criteria, using FDA definitions for ABSSSI

1 Archives of Internal Medicine, 2008, A.L. Hersh et.al.

Multiple Objectives

•Assess safety and pharmacokinetics

•Demonstrate similar efficacy vs. active
comparator

•Guide dose selection for future clinical studies

7

Phase 2 Clinical Trial -- Design

Trial conducted in Canada & Europe (Russia, Ukraine)

Dosing:IV infusion 1x/day for 7 days (5 days on PMX-30063 +
2 days placebo; 7 days on daptomycin)

200 patients, 4 arms, 50 patients per arm

Interim analysis after first 80 patients

PatientScreening

MSSA/MRSA

Randomization

Low (0.40 mg/kg load; 0.30 mg/kg qd x 4d)

Comparator (daptomycin)

Placebo

Placebo

Placebo

Visit Assessments:

Day 7

Day 3

Continuous safety assessments and analysis

Evaluation post treatment

Day 28

Day 10

Medium (0.75 mg/kg load; 0.35 mg/kg qd x 4d)

High (1.0 mg/kg load; 0.35 mg/kg qd x 4d)

8

Phase 2 Clinical Trial-- Study Populations

	Low dose	Medium dose	High dose	daptomycin	Total patients
Per Protocol Population1	40	35	39	47	161
mITT Population2	43	37	45	47	172
ITT Population3	54	54	54	53	215

1 - Per Protocol Population:All patients who received ≥ 80% of study drug, were culture confirmed for Staph aureus, and

     were assessed

2 - mITT (modified Intent-to-Treat) Population:All patients with culture-confirmed Staph aureus

3 - ITT (Intent-to-Treat) Population:All patients who were randomized into the study

Rigorous Study Entry Criteria:

●All populations must meet FDA definition for ABSSSI

●PP and mITT require positive Staph aureus culture

●Photographic documentation at all time points

9

FDA Guidance - Baseline and Day 3 Assessment

Definitions per FDA Guidance for Industry, ABSSSI, August 2010

Lesion Size:

•≥ 75 sq. cm2(redness, edema, and/or induration)

Clinical Response:

•Cessation of spread or reduction in size of redness, edema, and/or
induration of lesion, and

•Resolution of fever

Clinical Failure:

•Death, continued fever, increase in size of redness, edema and /or
induration of lesion, administration of rescue antibiotictherapy

10

Clinical Response - Day 3
Per FDA ABSSSI Guidance

Clinical Response	Low dose	Medium dose	High dose	daptomycin
Per Protocol	85.0%	71.4%	89.7%	74.5%
mITT	81.4%	67.6%	77.8%	74.5%
ITT	79.6%	68.5%	75.9%	75.5%

Key Outcomes:

●Consistently high clinical response rates at all doses of PMX-30063

•Similar to daptomycin comparator

●Findings corroborate interim analysis

11

Clinical Response - Day 3
Per FDA ABSSSI Guidance

12

Clinical Response - Days 3 and 7
Per Study Analysis Plan

Day 3	Low dose	Medium dose	High dose	daptomycin
Per Protocol	97.5%	91.4%	92.3%	91.5%
mITT	95.3%	89.2%	82.2%	91.5%
ITT	94.4%	90.7%	81.5%	90.6%

Day 7	Low dose	Medium dose	High dose	daptomycin
Per Protocol	92.5%	94.3%	97.4%	95.7%
mITT	86.0%	91.9%	84.4%	95.7%
ITT	87.0%	92.6%	83.3%	96.2%

Clinical response = cure + improvement

13

Clinical Response - Confidence Intervals
Per Study Analysis Plan - Per Protocol Population

Day 3

Day 7

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

14

Clinical Response - Confidence Intervals
Per Study Analysis Plan - mITT Population

Day 3

Day 7

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

15

Clinical Response - Confidence Intervals
Per Study Analysis Plan - ITT Population

Day 3

Day 7

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

16

Sustained Clinical Response - Days 10 and 28
Per Study Analysis Plan

Day 10	Low dose	Medium dose	High dose	daptomycin
Per Protocol	92.3%	93.8%	100%	97.7%
mITT	87.8%	93.9%	97.3%	97.7%
ITT	90.2%	91.8%	95.5%	97.9%

Day 28	Low dose	Medium dose	High dose	daptomycin
Per Protocol	97.2%	87.5%	100%	97.8%
mITT	97.2%	87.9%	100%	97.8%
ITT	95.7%	89.6%	95.6%	98.0%

Sustained Response at Day 28 for Day 10 Clinical Successes

Sustained Response at Day 10 for Day 3 Clinical Successes

17

Sustained Clinical Response - Confidence Intervals
Per Study Analysis Plan - Per Protocol Population

Day 28

Day 10

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

18

Sustained Clinical Response - Confidence Intervals
Per Study Analysis Plan - mITT Population

Day 28

Day 10

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

19

Sustained Clinical Response - Confidence Intervals
Per Study Analysis Plan - ITT Population

Day 28

Day 10

●Results similar across all treatment groups

•All confidence intervals overlap

●Results consistent in all populations (PP, mITT, ITT)

20

Time-to-Clinical Response Assessment
Per Protocol Population

Subjects who demonstrate at least 80% decrease in lesion size from baseline, and had a 2-point reduction
from baseline in severity for all signs and symptoms or no presence of all signs and symptoms.

21

Time-to-Clinical Response Assessment
mITT Population

22

Time-to-Clinical Response Assessment
ITT Population

23

Safety Analysis
Safety Population; N=215

	Low dose (n=52)	Medium dose (n=54)	High dose (n=54)	daptomycin (n=55)
Treatment Related Adverse Events
Excluding numbness & tingling	9.6% (5)	5.6% (3)	7.4% (4)	10.9% (6)
Numbness & tingling	65.4% (34)	64.8% (35)	87.0% (47)	1.8% (1)
Total TRAE	75.0% (39)	70.4% (38)	94.4% (51)	12.7% (7)
Discontinued due to TRAE	1.9% (1)	3.7% (2)	9.2% (5)	0

Numbness & tingling was most common TRAE

•No patient discontinued drug because of numbness/tingling

•Most cases were mild

•Completely transient, all resolved

•Mechanism thoroughly studied

24

Safety Analysis
Safety Population; N=215

	Low dose (n=52)	Medium dose (n=54)	High dose (n=54)	daptomycin (n=55)
Serious Adverse Events	1.9% (1)	3.7% (2)	3.7% (2)	0
TRSAE	1.9% (1)	1.8% (1)	1.8% (1)	0
Discontinued due to TRSAE	0	1.8% (1)	1.8% (1)	0

3 patients experienced a TRSAE

Hypertension- 1 medium dose; 1 high dose (both discontinued)

Increased platelets- 1 low dose

25

Patient Received Low Dose PMX-30063

Pre-treatment

Day 10

Day 3

26

Patient Received Medium Dose PMX-30063

Pre-treatment

Day 10

Day 3

27

Patient Received High Dose PMX-30063

Pre-treatment

Day 10

Day 3

28

Phase 2 ABSSSI Clinical Trial - Conclusions

Excellent clinical efficacy results for a first phase 2 study

Efficacy:

•High clinical response rates

•Similar across all treatment groups (95% CIs overlap)

•Efficacy comparable to active control (daptomycin)

•Early & sustained clinical response

•Results corroborateInterim Analysis

•Rigorous study entry criteria, using FDA definitions for ABSSSI

Safety:

•PMX-30063 is safe and generally well-tolerated

•Other than expected numbness & tingling, consistently low TRAE’s

29

Anticipated Next Steps

Continued regulatory efforts

Presentation of data at scientific meeting

Initiate Second Phase 2 trial in 2012

•Optimize dosing

•Maximize efficacy

•Maximize safety

•Study single dose regimen(s)

Goal: initiate pivotal trials in 2013

30

Goals for PMX-30063

First-line therapy for Staph aureus including resistant strains like MRSA

Short course therapy would promote

•Patient compliance

•Pharmacoeconomic benefits

Novel Defensin-Mimetic mechanism of action

•Active in preclinical studies vs. bacteria that are resistant to current antibiotics

•Resistance should be unlikely to develop to PMX-30063

•Multi-functional mechanism

Expand development for other potential indications and modes of delivery

•i.v.: pneumonia, bacteremia

•Topical oral rinse: oral mucositis (cancer)

31

Q & A

32

Why use PMX-30063 Antibiotic?

New mechanism and class of drug - “Defensin-Mimetic”

•Unlikely to encounter a resistant strain

•Unlikely to develop resistance in the future

Short course of therapy possible

•Next clinical trial plan to evaluate single dose regimen(s)

•Goal to shorten hospital stays, reduce healthcare costs, potential out-
patient treatment

Broader spectrum than other drugs for ABSSSI

Multi-functional mechanism - anti-biofilm, anti-inflammatory

•Additional indications possible - bacteremia, pneumonia

•Additional applications possible - cancer oral mucositis

33

No resistance seen for PMX-30063 vs. daptomycin in pre-clinical
studies

After 40 Passages, no resistance developed to PMX-30063

APIC, 2008, resistance

rates in U.S.

34

PMX-30063 - Successful Phase 2 Results

Efficacy demonstrated

Safety demonstrated

Entirely novel drug - goal to dominate the antibiotic market

Plan to advance with further clinical development

35

OTCBB: PYMX

www.polymedix.com

Revolutionizing the Treatment of Infectious
Diseases with Defensin-Mimetics